Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

John A. Ligon(University of Florida Health), John Glod(National Institutes of Health), Naomi Taylor(National Institutes of Health), Mary Frances Wedekind(National Cancer Institute), Amanda Carbonell(National Cancer Institute), Michael I. Barbato(Center for Drug Evaluation and Research), Xia Xu(Leidos (United States)), Josquin Moraly(Inserm), Haiyan Lei(National Cancer Institute), Cody J. Peer(National Institutes of Health), Paul S. Meltzer(National Cancer Institute), Markku Miettinen(National Institutes of Health), Jaydira Del Rivero(National Institutes of Health), King C. Chan(Leidos (United States)), Ramaprasad Srinivasan(National Cancer Institute), R. Taylor Sundby(National Cancer Institute), Seth M. Steinberg(National Institutes of Health), Richard Piekarz(Yeshiva University), Þorkell Andrésson(National Institutes of Health), Sara Zimmerman(National Institutes of Health), Eva Dombi(National Institutes of Health), Lee J. Helman(American Osteopathic Association), Karel Pacák(Endocrine Society), Brigitte C. Widemann(National Cancer Institute), William D. Figg(National Cancer Institute), Melissa Spencer(National Cancer Institute), Fernanda I. Arnaldez(MacroGenics (United States)), Lori Wiener(National Institutes of Health), Stephen Fox(Leidos (United States)), Jonathan Keith Killian(GlobalFoundries (United States)), W. Marston Linehan(National Cancer Institute), Jack F. Shern(National Institutes of Health)
Unknown
November 25, 2025
Cited by 0


Related Papers